Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency

Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Bedson Building, Newcastle University, Newcastle NE1 7RU, United Kingdom.
Journal of Medicinal Chemistry (Impact Factor: 5.45). 02/2011; 54(5):1233-43. DOI: 10.1021/jm1011929
Source: PubMed


Inhibition of the MDM2-p53 interaction has been shown to produce an antitumor effect, especially in MDM2 amplified tumors. The isoindolinone scaffold has proved to be versatile for the discovery of MDM2-p53 antagonists. Optimization of previously reported inhibitors, for example, NU8231 (7) and NU8165 (49), was guided by MDM2 NMR titrations, which indicated key areas of the binding interaction to be explored. Variation of the 2-N-benzyl and 3-alkoxy substituents resulted in the identification of 3-(4-chlorophenyl)-3-((1-(hydroxymethyl)cyclopropyl)methoxy)-2-(4-nitrobenzyl)isoindolin-1-one (74) as a potent MDM2-p53 inhibitor (IC(50) = 0.23 ± 0.01 μM). Resolution of the enantiomers of 74 showed that potent MDM2-p53 activity primarily resided with the (+)-R-enantiomer (74a; IC(50) = 0.17 ± 0.02 μM). The cellular activity of key compounds has been examined in cell lines with defined p53 and MDM2 status. Compound 74a activates p53, MDM2, and p21 transcription in MDM2 amplified cells and shows moderate selectivity for wild-type p53 cell lines in growth inhibition assays.

26 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: A library of novel 3-aryl isoindolinone derivatives with aromatic amino acid derivative fragments was designed and synthesized. Two synthetic routes were employed to construct 3-aryl isoindolinone ring system for different amino acid derivatives.
    Chemical Research in Chinese Universities 06/2013; 29(3). DOI:10.1007/s40242-013-2294-5 · 0.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Construction of a new benzene via the electrocyclization of diene-allene is an efficient protocol to access polysubstituted benzenes from simple, readily available starting materials. In this paper, we present a comprehensive study of a heteroatom-promoted propargyl-allenyl isomerization and electrocyclization for the facile and efficient synthesis of polyfunctionalized benzenes and naphthalenes. As a result of the readily accessible starting materials, simple operation, and mild conditions, this reaction should be an appealing strategy in organic synthesis.
    The Journal of Organic Chemistry 06/2011; 76(11):4582-90. DOI:10.1021/jo2004555 · 4.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The p53 tumour suppressor blocks cancer development by triggering apoptosis or cellular senescence in response to oncogenic stress or DNA damage. Consequently, the p53 signalling pathway is virtually always inactivated in human cancer cells. This unifying feature has commenced tremendous efforts to develop p53-based anti-cancer therapies. Different strategies exist that are adapted to the mechanisms of p53 inactivation. In p53-mutated tumours, delivery of wild-type p53 by adenovirus-based gene therapy is now practised in China. Also, remarkable progress has been made in the development of p53-binding drugs that can rescue and reactivate the function of mutant or misfolded p53. Other biologic approaches include the development of oncolytic viruses that are designed to specifically replicate in and kill p53-defective cells. Inactivation of wt-p53 frequently results from dysregulation of MDM2, an E3 ligase that regulates p53 levels. Small-molecule drugs that inhibit the interaction of MDM2 and p53 and block p53 degradation are currently tested in clinical trials. This survey highlights the recent developments that attempt to modulate the function of p53 and outlines strategies that are being investigated for pharmacological intervention in the p53 pathway.
    British Journal of Pharmacology 06/2011; 165(2):328-44. DOI:10.1111/j.1476-5381.2011.01570.x · 4.84 Impact Factor
Show more